38 results about "Vein graft" patented technology

Stents and methods of using stents are provided. Stents of the invention provide external support structure for a blood vessel segment disposed within, wherein the stents are capable of resilient radial expansion in a manner mimicking the compliance properties of an artery. The stent may be formed of a knitted or braided mesh formed so as to provide the needed compliance properties. A venous graft with the stent and a vein segment disposed within is provided, wherein graft is capable of mimicking the compliance properties of an artery. Methods of selecting stents for downsizing and methods of using the stents of the invention in downsizing and smoothening are provided. Methods of replacing a section of an artery with a venous graft including a stent of the invention are provided. Methods of reducing intimal hyperplasia in implanted vein segment in a venous graft using stents of the invention are provided.

An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, for instance, the arteriovenous graft system includes a first valve device positioned at the arterial end and a second valve device positioned at the venous end. In one embodiment, the valve devices may include an inflatable balloon that, when inflated, constricts and closes off the arteriovenous graft. By minimizing or preventing arterial steal, other complications associated with arteriovenous grafts are also avoided. For instance, the present invention is also well suited to preventing arteriovenous graft thrombosis, eliminating dialysis needle hole bleeding, and eliminating or minimizing arteriovenous graft pseudoaneurism formation.

The present invention provides a kit apparatus and a methodology to prevent the primary causes of arterio-venous graft thrombosis; and provides a durable vascular access for successful long term use in hemodialysis. The invention employs a patient-customized prosthetic endograft as an subcutaneously implanted vascular access; and utilizes a surgical method for endovascular insertion of the prosthetic endograft into a pre-chosen vein, which does not require a distal anastomosis, and thus allows the distal outflow end of the implanted vascular access to remain unattached and freely floating at a precisely located anatomic position within the internal lumen the pre-chosen vein.

A venous graft for replacement of a section of an artery and methods of making the graft. The graft comprises a flexible, resilient, generally tubular external support and a vein segment carried within and having an ablumenal surface in contact with and supported by the tubular support, the venous graft being capable of resilient radial expansion in a manner mimicking the radial compliance properties of an artery.

A venous graft for replacement of a section of an artery and methods of making the graft. The graft comprises a flexible, resilient, generally tubular external support and a vein segment carried within and having an ablumenal surface in contact with and supported by the tubular support, the venous graft being capable of resilient radial expansion in a manner mimicking the radial compliance properties of an artery.

The present invention provides a kit apparatus and a methodology to prevent the primary causes of arteriovenous graft thrombosis; and provides a durable vascular access for successful long term use in hemodialysis. The invention employs a patient-customized prosthetic endograft as an subcutaneously implanted vascular access; and utilizes a surgical method for endovascular insertion of the prosthetic endograft into a pre-chosen vein, which does not require a distal anastomosis, and thus allows the distal outflow end of the implanted vascular access to remain unattached and freely floating at a precisely located anatomic position within the internal lumen the pre-chosen vein.

A modular graft assembly includes a main graft, a lower extender cuff and an upper extender cuff. By rotating and / or telescoping the main graft, the lower extender cuff, and the upper extender cuff relative to one another, variations in the radial and longitudinal positions of branch vessels are readily accommodated by the modular graft assembly. Accordingly, an aneurysm in a main vessel is excluded while at the same time collateral flow to branch vessels is provided. Further, custom fabrication of a graft assembly to accommodate the vessel structure of a particular patient and the associated costs are avoided.

A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one or more therapeutic agents or substances, with the carrier including at least one coating on the surface thereof, and the coating associated with the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.

An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, for instance, the arteriovenous graft system includes a first valve device positioned at the arterial end and a second valve device positioned at the venous end. In one embodiment, the valve devices may include an inflatable balloon that, when inflated, constricts and closes off the arteriovenous graft. By minimizing or preventing arterial steal, other complications associated with arteriovenous grafts are also avoided. For instance, the present invention is also well suited to preventing arteriovenous graft thrombosis, eliminating dialysis needle hole bleeding, and eliminating or minimizing arteriovenous graft pseudoaneurism formation.

Constructs including a tubular biodegradable polyglycolic acid scaffold may be coated with extracellular matrix proteins and are substantially acellular. The constructs can be utilized as an arteriovenous graft, a coronary graft, an arterial graft, a venous graft, a duct graft, a skin graft, or a urinary graft or conduit.

An angioplasty balloon catheter with an added channel for delivering medication or removing body fluids distal to the site of angioplasty is disclosed. The balloons are especially useful in the treatment of occlusions in saphenous vein grafts, the coronary and carotid arteries, arteries arising from the aorta and branches thereof and in veins flowing to the heart or their tributaries and sub tributaries thereof.

An angioplasty balloon catheter with an added channel for delivering medication or removing body fluids distal to the site of angioplasty is disclosed. The balloons are especially useful in the treatment of occlusions in saphenous vein grafts, the coronary and carotid arteries, arteries arising from the aorta and branches thereof and in veins flowing to the heart or their tributaries and sub tributaries thereof.

An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, a subcutaneous arteriovenous graft system is described. The system includes an arteriovenous graft having an arterial end and an opposite venous end with a first valve device positioned at the arterial end of the arteriovenous graft and a second valve device positioned at the venous end of the arteriovenous graft. The system also includes an actuator having an accumulator. The actuator is in communication with both the first valve device and the second valve device and is configured to cause each valve device to open or close simultaneously. The accumulator assists in maintaining a generally constant pressure when the actuator causes each valve device to close.

A composite vascular graft is provided, which incorporates bioactive agents that can be controllably delivered to the implantation site to deliver therapeutic materials and / or to reduce infection of the implant. The vascular graft of the present invention includes a luminal layer of ePTFE; and a biodegradable polymer layer including a bioactive agent, such as an antimicrobial agent. The biodegradable polymer layer is posited on the external surface of the luminal ePTFE layer. The graft also includes a fabric layer, which is posited on the external surface of the biodegradable layer. The graft is particularly useful as an arterial-venous graft for hemodialysis procedures.

An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, for instance, the arteriovenous graft system includes a first valve device positioned at the arterial end and a second valve device positioned at the venous end. In one embodiment, the valve devices may include an inflatable balloon that, when inflated, constricts and closes off the arteriovenous graft. By minimizing or preventing arterial steal, other complications associated with arteriovenous grafts are also avoided. For instance, the present invention is also well suited to preventing arteriovenous graft thrombosis, eliminating dialysis needle hole bleeding, and eliminating or minimizing arteriovenous graft pseudoaneurism formation.

Stretch-induced increased hemodynamic load adversely affects endothelial cell function and is an important contributor to thromboembolus formation in heart failure, valvular heart disease, atrial fibrillation, venous insufficiency, and pulmonary hypertension, and in thrombus occluded vein grafts. Local thrombus formation and thromboenbolic events can be reduced by inhibiting the TGF-beta signaling pathway or TGF-beta per se. Inhibitors can be administered to patients or veins (prior to interposition) at risk for thromboembolic events or local thrombus formation. Inhibitors can be applied to harvested veins to be used as arterial grafts.

The invention provides a tubular tool for acquiring a human vein transplant in a minimally invasive manner. The tubular tool comprises a tubular tool bit, a tunnel tube and a handle which are sequentially connected and is characterized in that one end of the tool bit is an edge; the inner wall of the tool bit is provided with an annular protruding part which is close to the side, with the edge, ofthe tool bit. The tubular tool has the advantages that the vein transplant can be acquired in an minimally invasive manner, a large skin cut is avoided, and the tubular tool is fast to operate, simple, practicable, capable of saving time and labor and capable of greatly reducing medical treatment cost and the wound of a patient; a long skin cut and a large subcutaneous tissue wound are avoided, the tubular tool rotates and moves forwardly to separate the vein from peripheral tissue and cut off vein peripheral collateral branches while the main part of the vein transplant is kept intact, the main part of the vein transplant is guided into the tunnel tube, the vein is cut off and the transplant is taken out after required acquiring length is reached, and a minimally invasive effect is guaranteed.

The invention relates to a biodegradable extravascular stent and a preparation method thereof. The biodegradable extravascular stent comprises a biodegradable material film and is characterized in that taxol is dispersed in the biodegradable material film. The invention also provides a preparation method of the biodegradable extravascular stent, which is characterized by comprising the following concrete steps of: preparing a polycaprolactone and ethylene carbonate copolymer solution; adding a taxol solution; stirring uniformly; carrying out electrostatic spinning; and standing at room temperature to enable a solvent to volatilize, thereby obtaining a polycaprolactone and ethylene carbonate copolymer film in which the taxol is dispersed. The biodegradable extravascular stent obtained by the invention has an external support effect on vein grafts, can prevent and treat excessive proliferation of the tunica intima of the vein through drugs, and can avoid the risk of thrombosis caused by a drug eluting stent.

A venous graft for replacement of a section of an artery and methods of making the graft. The graft comprises a flexible, resilient, generally tubular external support and a vein segment carried within and having an ablumenal surface in contact with and supported by the tubular support, the venous graft being capable of resilient radial expansion in a manner mimicking the radial compliance properties of an artery.

Methods and devices for perfusing a blood vessel during the entire course of an end-to-side or end-to-end anastomosis procedure. One method can be used to form an end-to-side anastomosis of a saphenous vein graft to a coronary artery during an off-pump, beating heart, coronary artery bypass graft. In this example, the distal end of an elongate tube carrying a saphenous vein graft is advanced into an arteriotomy distal to an occlusion in the coronary artery. Perfusing blood flow is provided through the tube to the coronary artery, the vein graft is advanced over the tube to the arteriotomy and sutured completely to the coronary artery. The elongate tube can be retracted through the now secured vein graft, and the coronary artery supplied again from the proximal end of the vein graft. Some tubular devices include a reversibly expandable distal region, to form a seal between the inserted tube and the coronary artery being perfused, to prevent blood flow into the surgical field.

The present invention is directed to methods of treating a patient to prevent vein graft failure by administering a compound that inhibits the Notch signaling pathway.

A ring device is integrated externally onto and around a regular hemodialysis arterio-venous graft conduit. The ring device is adjustable to reduce or to normalize (by rebounding) the diameter of the graft, and eventually to change blood flow through the graft. This ring device is designed such that it can be scaled up or down to change its diameter, and simultaneously the diameter of the associated graft prior to and even after its implantation into a patient's arm or leg. Since a hemodialysis arterio-venous graft is usually implanted superficially underneath skin, the device and its adjustable parts can be electively or urgently located and operated from outside by touching and pushing the skin, subcutaneous tissues and the device without a surgical incision. The ring device can be located anywhere within the graft and can function with a single ring or as a set of multiple rings.

The invention provides a degradable outer stent and a preparation method and application of the stent. The degradable outer stent comprises a chimeric material and a delivery substance, the chimeric material comprises a degradable polymer substrate and a liquid metal material embedded in the degradable polymer substrate, and the delivery material is arranged on the surface of the liquid metal material; the degradable outer stent is mainly used in coronary artery bypass grafting, peripheral artery bypass grafting or artificial arteriovenous fistula surgery, can be implanted in the peripheral ofa vein graft or the peripheral of other pathological dilated vessels, and plays a role of mechanical support; in addition, the liquid metal material with specific morphology and composition are selected in the degradable outer stent, and extensive electroporation of vascular wall can be realized, so as to deliver plasmids, drugs, proteins and other substances; and the integration of electroporation into the outer stent with purely mechanical support, so as to improve the effect of the outer stent on inhibiting intimal hyperplasia of vein.

The present invention relates to extravascular supports. In particular, to extravascular supports which are used in vein grafting. More in particular, it relates to extravascular supports which are biodegradable.

One aspect of the invention provides a vessel treatment system including: a housing defining at least one opening adapted and configured to receive an anatomical vessel; and a humidifier in communication with the housing, the humidifier adapted and configured to introduce humidity into the housing to prevent desiccation of the anatomical vessel. Another aspect of the invention provides a kit including: the vessel treatment system as described herein; and a passivation agent. Another aspect of the invention provides a method for preparing a vein graft. The method includes: applying a tissue passivation agent to a resected anatomical vessel; and placing the resected anatomical vessel in a humidified chamber while the tissue passivation agent cures.

The present invention is directed to methods of treating a patient to prevent vein graft failure by administering a compound that inhibits the Notch signaling pathway.

The present invention discloses a method for treating AV graft failure in a patient in need thereof, said method comprising administering to said patient an effective dose of a formulation capable of inhibiting chymotrypsin To generate, release, or inhibit the formation of neointima, the effective dose of the preparation is the dose that can effectively treat the failure of the AV graft.

Methods and devices for perfusing a blood vessel during the entire course of an end-to-side or end-to-end anastomosis procedure. One method can be used to form an end-to-side anastomosis of a saphenous vein graft to a coronary artery during an off-pump, beating heart, coronary artery bypass graft. In this example, the distal end of an elongate tube carrying a saphenous vein graft is advanced into an arteriotomy distal to an occlusion in the coronary artery. Perfusing blood flow is provided through the tube to the coronary artery, the vein graft is advanced over the tube to the arteriotomy and sutured completely to the coronary artery. The elongate tube can be retracted through the now secured vein graft, and the coronary artery supplied again from the proximal end of the vein graft. Some tubular devices include a reversibly expandable distal region, to form a seal between the inserted tube and the coronary artery being perfused, to prevent blood flow into the surgical field.